Abaxis markets the system under the name VetScan® in the veterinary market and under the name Piccolo® in the human medical market. The company is developing a wider range of tests to penetrate the human diagnostic market. The Abaxis Piccolo and VetScan systems have set a new standard in point-of-care diagnostics. These simple, portable, easy-to-use chemistry panel systems are marketed to decentralized clinical environments where sample logistics, patient transportation, and result-reporting problems have a significant impact on the quality of patient care.

By targeting such facilities and practices, Abaxis' product strategy is to provide clinicians and veterinarians with diagnostic tools to evaluate general health, organ function and disease status and to monitor therapies. Abaxis product development is driven by the requirements of the marketplace. Test methods and panels are first developed to gain entry into new markets. Follow-on test panels are later offered to address other specific needs in each target market.